UPPSALA, Sweden, Jan. 31, 2019 /PRNewswire/ -- As previously announced, Biotage AB (publ) (Biotage) has during January 2019 issued 487,337 new shares in connection with the acquisition of PhyNexus, Inc.
Prior to the issue, the total number of outstanding shares and votes in Biotage was 64,714,447. Through the issue the number of shares in Biotage increased by 487,337, corresponding to 487,337 votes. Today, the last trading day of the month, the total number of shares and votes in Biotage is 65,201,784.
This is information that Biotage AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30CET on January 31, 2019.
Box 8 751 03 UPPSALA
Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage's products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)